Literature DB >> 20818856

Early-stage Hodgkin's lymphoma.

James O Armitage1.   

Abstract

Entities:  

Mesh：

Year:  2010        PMID： 20818856     DOI： 10.1056/NEJMra1003733

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  40 in total

1.  Hematological cancer: Localized non-bulky Hodgkin lymphoma--future questions.

Authors:  Bertrand Coiffier; Olivier Casasnovas
Journal:  Nat Rev Clin Oncol       Date:  2012-01-31       Impact factor: 66.675

Review 2.  Appropriate surveillance for late complications in patients in remission from Hodgkin lymphoma.

Authors:  Deborah L Darrington; Julie M Vose
Journal:  Curr Hematol Malig Rep       Date:  2012-09       Impact factor: 3.952

3.  Supportive/palliative care in cancer patients: quo vadis?

Authors:  Jean Klastersky; Isabelle Libert; Bénédicte Michel; Myriam Obiols; Dominique Lossignol
Journal:  Support Care Cancer       Date:  2015-10-14       Impact factor: 3.603

Review 4.  Update on the role of brentuximab vedotin in classical Hodgkin lymphoma.

Authors:  Sarah Tomassetti; Alex F Herrera
Journal:  Ther Adv Hematol       Date:  2018-07-12

5.  The importance of testing PET-directed therapy in patients with Hodgkin lymphoma.

Authors:  James O Armitage
Journal:  Curr Hematol Malig Rep       Date:  2011-09       Impact factor: 3.952

6.  Serial diffusion MRI to monitor and model treatment response of the targeted nanotherapy CRLX101.

Authors:  Thomas S C Ng; David Wert; Hargun Sohi; Daniel Procissi; David Colcher; Andrew A Raubitschek; Russell E Jacobs
Journal:  Clin Cancer Res       Date:  2013-03-26       Impact factor: 12.531

7.  Patients with testicular cancer undergoing CT surveillance demonstrate a pitfall of radiation-induced cancer risk estimates: the timing paradox.

Authors:  Pari V Pandharipande; Jonathan D Eisenberg; Richard J Lee; Michael E Gilmore; Ekin A Turan; Sarabjeet Singh; Mannudeep K Kalra; Bob Liu; Chung Yin Kong; G Scott Gazelle
Journal:  Radiology       Date:  2012-12-18       Impact factor: 11.105

8.  A phase I study of pulse high-dose vorinostat (V) plus rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) in patients with relapsed lymphoma.

Authors:  Lihua E Budde; Michelle M Zhang; Andrei R Shustov; John M Pagel; Ted A Gooley; George R Oliveira; Tara L Chen; Nancy L Knudsen; Jennifer E Roden; Britt E Kammerer; Shani L Frayo; Thomas A Warr; Thomas E Boyd; Oliver W Press; Ajay K Gopal
Journal:  Br J Haematol       Date:  2013-01-29       Impact factor: 6.998

9.  Improving Outcome of Hodgkins Disease with Autologous Hematopoietic Stem Cell Transplantation.

Authors:  Shreeniwas Raut; Sandip Shah; Kamalesh Shah; Kinnari Patel; Shailesh Talati; Sonia Parikh; Asha Anand; Harsha Panchal; Apurva Patel; Akhil Jain
Journal:  Indian J Hematol Blood Transfus       Date:  2015-05-30       Impact factor: 0.900

10.  PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.

Authors:  Margaretha G M Roemer; Ranjana H Advani; Azra H Ligon; Yasodha Natkunam; Robert A Redd; Heather Homer; Courtney F Connelly; Heather H Sun; Sarah E Daadi; Gordon J Freeman; Philippe Armand; Bjoern Chapuy; Daphne de Jong; Richard T Hoppe; Donna S Neuberg; Scott J Rodig; Margaret A Shipp
Journal:  J Clin Oncol       Date:  2016-04-11       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.